Compare · DXCM vs HIND
DXCM vs HIND
Side-by-side comparison of DexCom Inc. (DXCM) and Vyome Holdings Inc. (HIND): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HIND operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.95B, about 2210.2x HIND ($14.5M).
- Over the past year, DXCM is up 12.1% and HIND is down 72.2% - DXCM leads by 84.3 points.
- DXCM has been more active in the news (14 items in the past 4 weeks vs 7 for HIND).
- DXCM has more recent analyst coverage (25 ratings vs 1 for HIND).
- Company
- DexCom Inc.
- Vyome Holdings Inc.
- Price
- $84.69+1.96%
- $2.08+0.97%
- Market cap
- $31.95B
- $14.5M
- 1M return
- -7.44%
- -6.73%
- 1Y return
- +12.11%
- -72.19%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 14
- 7
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
- EVP, Chief Financal Officer Sylvain Jereme M sold $302,936 worth of shares (3,638 units at $83.27) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 146,828 units (SEC Form 4)
- Director Boehnlein Glenn S was granted 5,841 shares (SEC Form 4)
- New insider Boehnlein Glenn S claimed ownership of 42 shares (SEC Form 3)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Appoints Glenn Boehnlein to Board of Directors
- Dexcom Announces Upcoming Conference Presentation
- EVP Chief People & Culture Off Stern Sadie sold $226,669 worth of shares (2,565 units at $88.37) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 126,043 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
Latest HIND
- Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
- SEC Form 4 filed by Vyome Holdings Inc.
- Chardan Capital Markets initiated coverage on Vyome Holdings with a new price target
- SEC Form 3 filed by new insider Leonard Jerry
- Vyome Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
- SEC Form 10-Q filed by Vyome Holdings Inc.
- Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
- Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits